Tag Archives: Basel

The European Commission approved Novartis drug Lucentis as first effective anti-VEGF treatment for myopic choroidal neovascularization

Posted on 5, July 2013 by EuropaWire PR Editors

Lucentis® (ranibizumab) is the first licensed therapy to improve vision in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Pivotal trial shows average visual acuity improvement of up to 14 letters at one year with a median of … Read the full press release →

Posted in European Union, Government, Healthcare, Pharma & Biotech, Switzerland

Tagged Basel, choroidal neovascularization, CNV, Lucentis®, Novartis, RADIANCE, Tim Wright

Novartis announced US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to its serelaxin (RLX030) for acute heart failure

Posted on 2, July 2013 by EuropaWire PR Editors

Recognition by the US Food and Drug Administration (FDA) that RLX030 has the potential to address a serious unmet medical need If approved, RLX030 has the potential to be the first treatment breakthrough for Acute Heart Failure patients in 20 … Read the full press release →

Posted in Government, Healthcare, Pharma & Biotech, Science, Switzerland

Tagged acute heart failure, AHF, Basel, David Epstein, FDA, Novartis, RLX030, serelaxin, US Food and Drug Administration

Novartis’s omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with severe form of chronic skin disease CSU

Posted on 28, June 2013 by EuropaWire PR Editors

Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU)[1] Omalizumab found to be effective, safe and well tolerated in refractory CSU patients, including those on antihistamines at up to four … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Science, Switzerland

Tagged Basel, CIU, CSU, Dermatology, European Academy of Allergy and Clinical Immunology, GLACIAL, Novartis, Omalizumab, Tim Wright, World Allergy Organization, Xolair®

UBS AG announced the results of its Annual General Meeting held in May 2013

Posted on 4, June 2013 by EuropaWire PR Editors

Zurich / Basel, 4-6-2013 — /europawire.eu/ — At the Annual General Meeting held on May 2, 2013, UBS’s shareholders confirmed in their offices those members of the Board of Directors who had stood for re-election, and voted Reto Francioni onto the Board … Read the full press release →

Posted in Banks, Business, Financial, Management, Switzerland

Tagged Ann F. Godbehere, Annual General Meeting, Annual Report, Axel A. Weber, Axel P. Lehmann, Basel, Beatrice Weder di Mauro, Consolidated Financial Statements, David Sidwell, Ernst & Young AG, Helmut Panke, Isabelle Romy, Joseph Yam, Michel Demaré, Rainer-Marc Frey, Reto Francioni, shareholders, UBS, UBS AG, William G. Parrett, Zurich

Syngenta 1Q 2013 sales $4.6 billion

Posted on 8, May 2013 by EuropaWire PR Editors

Integrated regional sales up 8 percent at constant exchange rates Continuing momentum, growth across all regions High grower profitability supporting ongoing technology adoption Basel, Switzerland, 8-5-2013 — /europawire.eu/ — In the first quarter of 2013 integrated sales increased by 8 percent … Read the full press release →

Posted in Agriculture, Business, Chemicals, Financial, Switzerland

Tagged 1Q 2013, 1Q 2013 sales, acquisitions, ACTARA, AXIAL, Basel, cereals, corn herbicide CALLISTO, corn herbicides, corn seeds, CRUISER, divestments, Garden, herbicides, Lawn, Mike Mack, SEGURIS, soybean seeds, sunflower, Syngenta, TOUCHDOWN, VIBRANCE seed care

Syngenta: EU Member States again fail to agree restriction on key crop protection technology

Posted on 7, May 2013 by EuropaWire PR Editors

Basel, Switzerland, 7-5-2013 — /europawire.eu/ — Syngenta acknowledged that European Union (EU) Member States for the second time failed to agree on the European Commission’s proposal for a ban on neonicotinoid pesticides. The latest decision should compel the Commission to return to … Read the full press release →

Posted in Agriculture, Belgium, Business, Chemicals, European Union, Government, Law, Politics, Society, Switzerland

Tagged ban, Basel, bee health, bee health decline, disease, EFSA, health of bees, John Atkin, key crop protection technology, loss of habitat, neonicotinoid, neonicotinoid pesticides, Nutrition, Operation Pollinator initiative, Pesticides, Syngenta, viruses